Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

Considerations in using anticoagulant therapy in special patient populations.

Phillips KW, Dobesh PP, Haines ST.

Am J Health Syst Pharm. 2008 Aug 1;65(15 Suppl 7):S13-21. doi: 10.2146/ajhp080241.

PMID:
18653820
2.

Role of warfarin pharmacogenetic testing in clinical practice.

Tan GM, Wu E, Lam YY, Yan BP.

Pharmacogenomics. 2010 Mar;11(3):439-48. doi: 10.2217/pgs.10.8. Review.

PMID:
20402581
3.

Optimal dosing of warfarin and other coumarin anticoagulants: the role of genetic polymorphisms.

Daly AK.

Arch Toxicol. 2013 Mar;87(3):407-20. doi: 10.1007/s00204-013-1013-9. Epub 2013 Feb 2. Review.

PMID:
23376975
4.

Warfarin dosing and the promise of pharmacogenomics.

Dumas TE, Hawke RL, Lee CR.

Curr Clin Pharmacol. 2007 Jan;2(1):11-21. Review.

PMID:
18690851
5.

[Application of warfarin pharmacogenetics].

Tomek A, Mat'oska V, Kumstýrfová T, Táborský L.

Vnitr Lek. 2009 Jun;55(6):565-9. Review. Czech.

PMID:
19662888
6.

Pharmacogenetics of warfarin: current status and future challenges.

Wadelius M, Pirmohamed M.

Pharmacogenomics J. 2007 Apr;7(2):99-111. Epub 2006 Sep 19. Review.

PMID:
16983400
7.

Pharmacogenetics of vitamin K antagonists: useful or hype?

Lippi G, Franchini M, Favaloro EJ.

Clin Chem Lab Med. 2009;47(5):503-15. doi: 10.1515/CCLM.2009.140. Review.

PMID:
19397481
8.

Genetic influences on the response to warfarin.

Kamali F.

Curr Opin Hematol. 2006 Sep;13(5):357-61. Review.

PMID:
16888441
9.

Translation of pharmacogenetics into clinically relevant testing modalities.

Baudhuin LM, Langman LJ, O'Kane DJ.

Clin Pharmacol Ther. 2007 Oct;82(4):373-6. Review.

PMID:
17851577
10.

The pharmocogenomics of warfarin: closing in on personalized medicine.

Rettie AE, Tai G.

Mol Interv. 2006 Aug;6(4):223-7. Review.

PMID:
16960144
11.

Warfarin resistance.

Sinxadi P, Blockman M.

Cardiovasc J Afr. 2008 Jul-Aug;19(4):215-7. Review.

12.

Pharmacogenomics of 4-hydroxycoumarin anticoagulants.

Au N, Rettie AE.

Drug Metab Rev. 2008;40(2):355-75. doi: 10.1080/03602530801952187 . Review.

PMID:
18464049
13.

10 years of oral anticoagulant pharmacogenomics: what difference will it make? A critical appraisal.

Kurnik D, Loebstein R, Halkin H, Gak E, Almog S.

Pharmacogenomics. 2009 Dec;10(12):1955-65. doi: 10.2217/pgs.09.149. Review.

PMID:
19958094
14.

Warfarin therapy: influence of pharmacogenetic and environmental factors on the anticoagulant response to warfarin.

Siguret V, Pautas E, Gouin-Thibault I.

Vitam Horm. 2008;78:247-64. doi: 10.1016/S0083-6729(07)00012-X. Review.

PMID:
18374198
15.
16.

Genetic determinants of dose and clinical outcomes in patients receiving oral anticoagulants.

Schwarz UI, Stein CM.

Clin Pharmacol Ther. 2006 Jul;80(1):7-12. Review. No abstract available.

PMID:
16815312
17.

[Oral anticoagulation and pharmacogenetics: importance in the clinical setting].

Benusiglio PR, Desmeules J, de Moerloose P, Dayer P.

Rev Med Suisse. 2007 Sep 12;3(124):2030, 2033-4, 2036. Review. French.

PMID:
17955831
18.

[Pharmacogenetics of oral anticoagulants: individualized drug treatment for more efficacy and safety].

Loriot MA, Beaune P.

Rev Prat. 2007 Jun 30;57(12):1281-6. Review. French.

PMID:
17717937
19.

Pharmacogenetic testing for warfarin sensitivity.

Lyon E, McMillin G, Melis R.

Clin Lab Med. 2008 Dec;28(4):525-37. doi: 10.1016/j.cll.2008.09.001. Review.

PMID:
19059060
20.

Anticoagulants in older patients. A safety perspective.

Beyth RJ, Landefeld CS.

Drugs Aging. 1995 Jan;6(1):45-54. Review. Erratum in: Drugs Aging 1995 Apr;6(4):343.

PMID:
7696778

Supplemental Content

Support Center